approved

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

3 weeks ago

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

- The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging…

3 weeks ago

Avricore Grants Options

June 14, 2025 01:05 ET  | Source: Avricore Health Inc. VANCOUVER, British Columbia, June 14, 2025 (GLOBE NEWSWIRE) -- AVRICORE…

3 weeks ago

JZXN Raises Funds through Convertible Notes to Acquire Bitcoin, Initiating a Strategic Layout of Thousands of Bitcoins

HANGZHOU, China, June 11, 2025 /PRNewswire/ -- JZXN Holdings, Inc. (NASDAQ: JZXN; the "Company") announced that its board of directors has…

3 weeks ago

Ski Jumping: yellow and red card sanctions among changes to be introduced for equipmentrelated infractions in 2025/26

Jun 13, 2025 - Having reviewed a set of proposals by the Ski Jumping Sub-Committee for Equipment and Development during its…

3 weeks ago

BingX Listed as Approved VASP by Upbit Korea Under Travel Rule Framework

PANAMA CITY, June 13, 2025 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3 AI company, announced it has been officially…

3 weeks ago

Orezone Announces Results of Meeting of Shareholders

VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”)…

3 weeks ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

June 11, 2025 11:30 ET  | Source: Onconetix, Inc. CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:…

3 weeks ago

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the European Commission (EC) has granted conditional marketing authorisation…

4 weeks ago

Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…

4 weeks ago